ClinicalTrials.gg
CompletedNCT01070979Updated Apr 22, 2013Results posted

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

A Phase 3 interventional study of Estradiol acetate and Estradiol in Hormone Replacement Therapy, sponsored by Warner Chilcott. Completed at 32 sites in United States. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2013-04-22.

Sponsored by Warner Chilcott (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
35 Years and older
Sex
Female
01

Study summary

Multicenter, double-blind, controlled, parallel group, randomized study to compare the clinical benefit of Estradiol acetate tablets, estradiol tablets and conjugated equine estrogen tablets, each administered orally, once daily, to postmenopausal women.

02

Conditions studied

  • Hormone Replacement Therapy
03

In context

Lead sponsor

Warner Chilcott is the lead sponsor of 58 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

First submitted before Warner Chilcott became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 40 years of age; bilateral oophorectomy ≥ 35 years of age.
  2. Non-hysterectomized women:

    • Amenorrhea for ≥ 12 months or
    • Amenorrhea for ≤ 12 months, but longer than 6 months, and serum FSH (follicle stimulating hormone) levels > 40 units/L and serum estradiol levels \< 20 pg /mL,

    Hysterectomized women:

    • Bilateral oophorectomy - subjects may enter the study 6 weeks after surgery or
    • History of removal of ovaries may be confirmed by - serum FSH levels > 40 units/L and serum estradiol levels \< 20 pg/mL or via surgical report / ultrasound.
  3. Seven or more moderate or severe hot flushes daily for 1 week or 60 or more moderate or severe flushes in 1 week during the 2 week screening period prior to study entry.

Exclusion criteria

Exclusion Criteria:

  1. Hormone therapy administered via the following routes and during the specified timeframes: oral within 8 weeks, vaginal (rings, creams, gels) within 1 week, transdermal within 4 weeks, intramuscular within 6 weeks, progestational implants, estrogen or estrogen/progestational injectable drug therapy within 3 months, estrogen pellet or progestational injectable within 6 months.
  2. Abnormal Pap smear suggestive of low grade squamous intraepithelial lesion (LGSIL) or worse. Enrollment of subjects with an ASCUS (atypical squamous cells of undetermined significance) interpretation must be discussed with the sponsor prior to randomization.
  3. Urinary tract infection
  4. Congestive heart failure
  5. Uncontrolled hypertension; sitting systolic BP ≥ 160 mmHg or diastolic ≥ 95 mmHg
  6. History of stroke or
  7. Treatment with anticoagulants (heparin or warfarin).
  8. Uncontrolled thyroid disorders.
  9. Insulin-dependent diabetes mellitus.
  10. Increase frequency or severity of headaches including migraines during previous estrogen therapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    Estradiol acetate (E3A)

    Drug: Estradiol acetate

  • Active comparator
    Estradiol

    Drug: Estradiol

  • Active comparator
    Conjugated equine estrogens (CEE):

    Drug: Conjugated equine estrogens

Interventions

  • DrugEstradiol acetate

    Tablet containing 0.9 mg E3A, daily oral administration.

  • Tablet containing 1 mg estradiol, daily oral administration.

    Also known as: Estrace

  • Tablet containing 0.625 mg CEE, daily oral administration.

    Also known as: Premarin

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population

    Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep

    Time frame: Baseline to Week 4

  2. Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population

    Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population

    Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.

    Time frame: Baseline to Week 4

  2. Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population

    Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.

    Time frame: Baseline to Week 12

  3. Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population

    Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.

    Time frame: Baseline to Week 4

  4. Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population

    Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.

    Time frame: Baseline to Week 8

  5. Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population

    Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.

    Time frame: Baseline to Week 12

07

Results

Posted Apr 8, 2011

Participant flow

Enrollment of postmenopausal women for relief of hot flushes and urogenital symptoms beginning Feb '03 at 33 sites in the US.

Participant flow — Overall Study
MilestoneEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
Started798585
Completed687372
Not completed111213
Withdrew: Adverse event233
Withdrew: Lost to follow-up211
Withdrew: Protocol violation026
Withdrew: Surgery, moving, personal, abn. labs442
Withdrew: Withdrawal by subject311
Withdrew: No study drug taken010

Outcome measures

PrimaryMean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population

Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · Change in Hot Flush Count
Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population
Change in Hot Flush CountEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population-54.1 ± 4.5-62.0 ± 4.5-54.5 ± 4.3
SecondaryMean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population

Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · Change in Score
Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population
Change in ScoreEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population-0.53 ± 0.106-0.51 ± 0.106-0.59 ± 0.102
PrimaryMean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population

Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Change in Hot Flush Count
Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population
Change in Hot Flush CountEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population-63.6 ± 4.8-72.2 ± 4.7-67.2 ± 4.6
SecondaryMean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population

Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Change in Score
Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population
Change in ScoreEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population-1.05 ± 0.127-1.34 ± 0.125-1.17 ± 0.122
SecondaryMean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population

Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · Change in Score
Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population
Change in ScoreEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population-1.89 ± 0.413-2.26 ± 0.407-1.96 ± 0.398
SecondaryChange From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population

Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Change in Score
Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population
Change in ScoreEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population-1.96 ± 0.432-2.58 ± 0.425-2.42 ± 0.416
SecondaryChange From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population

Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Change in Score
Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population
Change in ScoreEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population-2.49 ± 0.437-2.59 ± 0.431-2.52 ± 0.422

Adverse events

Collected over 7 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Estradiol Acetate (E3A)—0/79 (0%)19/79 (24.1%)
Estradiol—1/84 (1.2%)25/84 (29.8%)
Conjugated Equine Estrogens (CEE)—0/85 (0%)30/85 (35.3%)
Most frequent serious events
Most frequent serious events
EventEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
metrorrhagiaReproductive system and breast disorders0/791/840/85
Most frequent other events
Most frequent other events
EventEstradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)
HeadacheNervous system disorders3/795/846/85
Breast TendernessReproductive system and breast disorders2/795/845/85
NauseaGastrointestinal disorders4/791/842/85
Abdominal DistentionGastrointestinal disorders1/794/842/85
MetrorrhagiaReproductive system and breast disorders2/793/844/85
AnxietyPsychiatric disorders3/790/842/85
NasopharyngitisNervous system disorders1/793/840/85
Vaginosis FungalInfections and infestations0/791/843/85
Weight IncreasedInvestigations1/791/843/85
ArthralgiaMusculoskeletal and connective tissue disorders2/792/843/85

Baseline characteristics

Age Continuous
Age Continuous(years)Estradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)Total
Mean52.2 ± 6.652.3 ± 7.053.8 ± 6.352.8 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)Estradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)Total
Female798585249
Male0000
Region of Enrollment
Region of Enrollment(participants)Estradiol Acetate (E3A)EstradiolConjugated Equine Estrogens (CEE)Total
United States798585249
08

Study locations

32 sites
  • Warner Chilcott Investigational Site
    Phoenix, Arizona 85031, United States
  • Warner Chilcott Investigational Site
    Carmichael, California 95608, United States
  • Warner Chilcott Investigational Site
    San Diego, California 92108, United States
  • Warner Chilcott Investigational Site
    San Diego, California 92123, United States
  • Warner Chilcott Investigational Site
    Aventura, Florida 33180, United States
  • Warner Chilcott Investigational Site
    Boynton Beach, Florida 33437, United States
  • Warner Chilcott Investigational Site
    Clearwater, Florida 33765, United States
  • Warner Chilcott Investigational Site
    Daytona Beach, Florida 32114, United States
  • Warner Chilcott Investigational Site
    Gainesville, Florida 32605, United States
  • Warner Chilcott Investigational Site
    Longwood, Florida 32779, United States
  • Warner Chilcott Investigational Site
    Melbourne, Florida 32935, United States
  • Warner Chilcott Investigational Site
    Miami, Florida 33143, United States
  • Warner Chilcott Investigational Site
    Palm Springs, Florida 33461, United States
  • Warner Chilcott Investigational Site
    Pinellas Park, Florida 33781, United States
  • Warner Chilcott Investigational Site
    Sarasota, Florida 34232, United States
  • Warner Chilcott Investigational Site
    Venice, Florida 34285, United States
  • Warner Chilcott Investigational Site
    Roswell, Georgia 30075, United States
  • Warner Chilcott Investigational Site
    Chicago, Illinois 60612, United States
  • Warner Chilcott Investigational Site
    Peoria, Illinois 61615, United States
  • Warner Chilcott Investigational Site
    Laurel, Maryland 20707, United States
  • Warner Chilcott Investigational Site
    Lincoln, Nebraska 68510, United States
  • Warner Chilcott Investigational Site
    Raleigh, North Carolina 27612, United States
  • Warner Chilcott Investigational Site
    Winston Salem, North Carolina 27103, United States
  • Warner Chilcott Investigational Site
    Cleveland, Ohio 44122, United States
  • Warner Chilcott Investigational Site
    Columbus, Ohio 43212, United States
  • Warner Chilcott Investigational Site
    Mogadore, Ohio 44260, United States
  • Warner Chilcott Investigational Site
    Portland, Oregon 97201, United States
  • Warner Chilcott Investigational Site
    Pittsburgh, Pennsylvania 15206, United States
  • Warner Chilcott Investigational Site
    Nashville, Tennessee 37203, United States
  • Warner Chilcott Investigational Site
    Salt Lake City, Utah 84124, United States
  • Warner Chilcott Investigational Site
    Spokane, Washington 99201, United States
  • Warner Chilcott Investigational Site
    Tacoma, Washington 98405, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Sep 2003 and a completion of Sep 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 7 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2010
First posted
Feb 18, 2010
Start
Feb 2003
Primary completionActual
Sep 2003
CompletionActual
Sep 2003
Results first posted
Apr 8, 2011
Last update
Apr 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01070979
Lead sponsor
Warner Chilcott
Responsible party
Sponsor
First posted
Feb 18, 2010
Start date
Feb 2003
Primary completion
Sep 2003
Completion
Sep 2003
Results posted
Apr 8, 2011
Last update
Apr 22, 2013

Study contacts

Herman Ellman, MD
study director · Warner Chilcott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion